-- Acquisition will allow Codex DNA to expand its commercial BioXp™ system and biofoundry service offerings, reduce raw material costs, and accelerate overall growth strategy -- SAN DIEGO, Nov. 09, ...
Codex DNA to contribute novel synthetic biology-based solutions to stop the spread of a global disease that continues to devastate the citrus industry SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- ...
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, ...
Todd R. Nelson, Ph.D., has served as the President, Chief Executive Officer and a member of the board of directors of Codex DNA (NASDAQ:DNAY) since July 2018. Prior to joining the company, Dr. Nelson ...
Codex DNA (DNAY) is a $267m market cap biotech that IPOd in June last year, raising $123m at $16 per share. The company was spun out of Synthetic Genomics (since renamed Viridos) in 2019, having been ...
One of the pioneers of synthetic biology can design vaccines against coronavirus and other pathogens in about an hour. Now, labs can put his methods to work on their own benchtops. In 2013, a ...
The company's share price blasted 39% higher because of an exciting new partnership. Under the terms of the deal, the two companies will work together to further develop Codex DNA's BioXP, which its ...
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World Vaccine ...
Good afternoon, ladies and gentlemen, and welcome to the Quarter 1 2022 Codex DNA Incorporated earnings conference call. [Operator instructions] I would now likely turn a conference over to your host, ...
Codex DNA will be releasing earnings Q2 on August 9. Wall Street analysts expect Codex DNA will release losses per share of $0.507. Watch Codex DNA stock price in real-time on Markets Insider here. On ...
Wednesday will go down in history for Codex DNA (NASDAQ: DNAY). The genetics-focused biotech saw its share price rocket 39% higher, thanks to a potentially very lucrative deal with a deep-pocketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback